Article Text

This article has a correction. Please see:

other Versions

PDF
Serelaxin and acute heart failure
  1. Jeremy Tietjens1,
  2. John R Teerlink1,2
  1. 1School of Medicine, University of California San Francisco, San Francisco, California, USA
  2. 2Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
  1. Correspondence to Dr John R Teerlink, San Francisco Department of Cardiology, VA Medical Center, 111C, Building 203, Room 2A-49, 4150 Clement Street, San Francisco, California 94121-1545 USA; john.teerlink{at}ucsf.edu

Abstract

Attempts at developing novel therapeutic agents for acute heart failure (AHF) over the past two decades have been marked by disappointment. Relaxin is a human peptide hormone believed to mediate many adaptive haemodynamic changes that occur during pregnancy. Because these effects may be useful for treating AHF, a recombinant version of human relaxin-2, serelaxin, has been developed as a novel therapeutic agent. Studies have confirmed serelaxin’s haemodynamic effects of decreasing pulmonary and systemic resistance and increasing renal blood flow. A 1161-patient, placebo-controlled Phase III trial, RELAX-AHF, demonstrated significant improvement in symptoms, reduced worsening of heart failure, decreased hospital length of stay and increased 180-day survival after index hospitalisation. Additional Phase III trials (RELAX-AHF-2; RELAX-AHF-ASIA) are underway to further evaluate the efficacy of serelaxin in patients with AHF. This article will review the physiological function, mechanism of action, clinical trial results and future directions of serelaxin in the treatment of AHF.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and British Cardiovascular Society